Date: 16/05/22 Your Name: Michela Verzè Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None	
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None		
	manuscript writing or educational events	2 2		
6	Payment for expert testimony	None		
7	Support for attending meetings and/or travel	None		in dias
8	Patents planned, issued or	None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	None		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None		
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non- financial interests	None		

Please place an "X" next to the following statement to indicate your agreement:

16/05/22, PARMA

Michele Veri

Date: 16/05/22 Your Name: Monica Pluchino Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 26 months
2	Grants or contracts from	None	
2	any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-	None	

Please place an "X" next to the following statement to indicate your agreement:

PARMA, 16/05/22

Voice Philo

Date: 06/05/2022 Your Name: Alessandro Leonetti Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

-			
5	Payment or honoraria for	Astra-Zeneca	Payment made to me
	lectures, presentations,	MSD	Payment made to me
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	_		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	Beigene	Payment made to me
	Safety Monitoring Board or Advisory Board	Sanofi	Payment made to me
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid		
11	Stock or stock options	None	
	_		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Alessandro Leonetti has received speakers' fees for Astra-Zeneca and MSD. Alessandro Leonetti has been on advisory boards for BeiGene and Sanofi.

Please place an "X" next to the following statement to indicate your agreement:

PANMA, 23/05/2022

des que

Date: 16/05/22 Your Name: Matilde Corianò Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u><u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	e frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
Time	e frame: past 36 months		
2	Grants or contracts from	None	
	any entity (if not indicated		
3	in item #1 above). Royalties or licenses	None	
5	Royantes of neelises	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Parma, 16/05/2022

leeder

Date: 16/05/22 Your Name: Francesco Bonatti Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
	, , , , , , , , , , , , , , , , , , ,		

Payment or honoraria for	None		
lectures, presentations,	السطيني أدو بينظر		
speakers bureaus, manuscript writing or educational events			
Payment for expert testimony	None		
Support for attending meetings and/or travel	None		
Patents planned, issued or pending	None		
Participation on a Data Safety Monitoring Board or Advisory Board	None		
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None		
Stock or stock options	None		
Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
Other financial or non-	None		
	lectures, presentations, speakers bureaus, manuscript writing or educational eventsPayment for expert testimonySupport for attending meetings and/or travelPatents planned, issued or pendingParticipation on a Data Safety Monitoring Board or Advisory BoardLeadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaidStock or stock optionsReceipt of equipment, materials, drugs, medical writing, gifts or other servicesOther financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational eventsNonePayment for expert testimonyNoneSupport for attending meetings and/or travelNonePatents planned, issued or pendingNoneParticipation on a Data Safety Monitoring Board or Advisory BoardNoneLeadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaidNoneReceipt of equipment, materials, drugs, medical writing, gifts or other servicesNoneReceipt of in on- NoneNone	lectures, presentations, speakers bureaus, manuscript writing or educational events None Payment for expert testimony None Support for attending meetings and/or travel None Patents planned, issued or pending None Participation on a Data Safety Monitoring Board or Advisory Board None Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Receipt of equipment, materials, drugs, medical writing, gifts or other services None Other financial or non- None

Please place an "X" next to the following statement to indicate your agreement:

PARNA 16.05.2022

Freezel?

Date: 16/05/22 Your Name: Maria Pia Armillotta Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
	신나 같은 것 이번째 것 것		<u> </u>
4	Consulting fees	None	
	_		

5	Payment or honoraria for	None	a se ala dila
	lectures, presentations,		1 - AAAD.
	speakers bureaus,		
	manuscript writing or		 Sort George 1
_	educational events		The Second Contract of Contrac
6	Payment for expert	None	
	testimony		
7	Support for attending	None	A la contrata de la c
	meetings and/or travel		
	and the second of the second		and the second
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
i de la	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11		None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		
		West from The second	

Please place an "X" next to the following statement to indicate your agreement:

Parma, 16/05/2022

Maria Pia Armillotta

Date: 16/05/2022 Your Name: Fabiana Perrone Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
Ŭ	testimony		
	,		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
-			
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

I have no conflict of interest.

Please place an "X" next to the following statement to indicate your agreement:



Date: 16/05/22

Your Name: HIRIAN CASACI Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10023636	e frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Tim	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

	÷.,		
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	19. de Carlos Norton, e ser la Colto e ser la Solto de Carlos de Carlos de Carlos de Carlos
11	Stock or stock options	None	
12	2 Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-	None	
19 19 19 19 19 19 19 19 19 19 19 19 19 1	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

PARMA, N7/5/21 Mendi

Date: 10/05/2022 Your Name: Roberta Minari Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time initiation this item.		
	e		
		Time frame: past	: 36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
1.17			
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	Novartis	Payment was made to me.
	educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	
2.1			

Roberta Minari has received payment for manuscript writing from Novartis

Please place an "X" next to the following statement to indicate your agreement:

10.05.22

PARMA

Date: 20/05/22 Your Name: Marcello Tiseo Manuscript Title: Role of ctDNA for the detection of minimal residual disease (MRD) in resected non-small cell lung cancer (NSCLC): a systematic review Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	None	
	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Institutional research grants from Astra-Zeneca, Boehringer Ingelheim.	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	BMS, Roche, Pfizer, Astra- Zeneca, Takeda, Sanofi	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
		- renew -	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Astra-Zeneca, Pfizer, Eli- Lilly, Novartis, Roche, MSD, Boehringer Ingelheim, Takeda, Amgen, Merck	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None	
13	Other financial or non- financial interests	None	

Conflict of interest: M.T. received speakers' and/or consultants' fee from Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Takeda, Amgen, Merck, Sanofi.

M.T. received institutional research grants from Astra-Zeneca, Boehringer Ingelheim.

Please place an "X" next to the following statement to indicate your agreement:

UNIVERSITÀ DI PARMA DIPARTIMENTO DI MEDICINA E CHIRURGIA Prof. Marcello Tiseo